BackGenerate Biomedicines Overview

Generate Biomedicines Long Term Debt

Generate Biomedicines's long-term debt is $51M.

Get informed when a big investor buys or sells

+ Follow
Long Term Debt
$51.31M

Peer average

Loading

Generate Biomedicines Long Term Debt History

Loading

Generate Biomedicines vs. peers: Long Term Debt Comparison

Loading

Generate Biomedicines Long Term Debt Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

Generate Biomedicines (GENB) FAQ

The latest long-term debt for GENB is $51M as of March 2026. Investors often review this figure alongside Generate Biomedicines's historical trend and sector peers before judging valuation or financial health.

A long-term debt figure of $51M for GENB is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting GENB's long-term debt ($51M), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.